These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 28042732)
1. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. Yiu ZZ; Warren RB Expert Opin Investig Drugs; 2017 Feb; 26(2):243-249. PubMed ID: 28042732 [TBL] [Abstract][Full Text] [Related]
2. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589 [TBL] [Abstract][Full Text] [Related]
3. Tildrakizumab for treating psoriasis. Galluzzo M; D'adamio S; Bianchi L; Talamonti M Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735 [TBL] [Abstract][Full Text] [Related]
4. Tildrakizumab for the treatment of psoriasis. Sinclair R; Thirthar Palanivelu V Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141 [No Abstract] [Full Text] [Related]
5. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965 [TBL] [Abstract][Full Text] [Related]
6. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis. Paton DM Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880 [TBL] [Abstract][Full Text] [Related]
7. Tildrakizumab for the treatment of psoriasis. Bangert C; Kopp T Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696 [TBL] [Abstract][Full Text] [Related]
8. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis. Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1). Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387 [TBL] [Abstract][Full Text] [Related]
10. Tildrakizumab: A Review of Phase II and III Clinical Trials. Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790 [TBL] [Abstract][Full Text] [Related]
11. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis. Frampton JE Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030 [TBL] [Abstract][Full Text] [Related]
12. Risankizumab for the treatment of psoriasis. Gu C; Yang J Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804 [No Abstract] [Full Text] [Related]
13. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis. Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661 [No Abstract] [Full Text] [Related]
14. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients. Drerup KA; Seemann C; Gerdes S; Mrowietz U Dermatology; 2022; 238(4):615-619. PubMed ID: 34775387 [TBL] [Abstract][Full Text] [Related]
15. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359 [TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693 [TBL] [Abstract][Full Text] [Related]
18. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060 [TBL] [Abstract][Full Text] [Related]
19. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274 [TBL] [Abstract][Full Text] [Related]
20. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]